scispace - formally typeset
S

Suzanne Vento

Researcher at New York University

Publications -  13
Citations -  539

Suzanne Vento is an academic researcher from New York University. The author has contributed to research in topics: Focal segmental glomerulosclerosis & Kidney disease. The author has an hindex of 7, co-authored 13 publications receiving 301 citations.

Papers
More filters
Journal ArticleDOI

An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome.

Christopher E. Gillies, +101 more
TL;DR: This study discovered GLOM and TI eQTLs, identified those that were tissue specific, deconvoluted them into cell-specific signals, and used them to characterize known GWAS alleles.
Journal ArticleDOI

Development and evaluation of deep learning-based segmentation of histologic structures in the kidney cortex with multiple histologic stains.

Catherine P. Jayapandian, +89 more
- 01 Jan 2021 - 
TL;DR: This largest study to date adapted deep learning for the segmentation of kidney histologic structures across multiple stains and pathology laboratories and validated deep learning networks for the segmentsation of histologic structure on kidney biopsies and nephrectomies.
Journal ArticleDOI

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease

Laura H. Mariani, +239 more
TL;DR: Study infrastructure will support a broad range of scientific approaches to identify mechanistically distinct subgroups, identify accurate biomarkers of disease activity and progression, delineate disease-specific treatment targets, and inform future therapeutic trials.
Journal ArticleDOI

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group

TL;DR: The findings suggest that future studies of novel therapies for rare glomerular diseases such as FSGS may benefit from enrollment of patients earlier in the course of their disease, and better identification of patients who are likely to respond to a new treatment based on biomarkers suggesting involvement of the disease pathway targeted by the experimental agent may reduce the required sample size and increase the likelihood of a favorable outcome.